

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 March 2009 (19.03.2009)

PCT

(10) International Publication Number  
**WO 2009/035535 A2**

(51) International Patent Classification:  
C07C 213/00 (2006.01)

(74) Agent: CHENG, Kent, H.; Cohen Pontani Lieberman & Pavane LLP, 551 Fifth Avenue, New York, NY 10176 (US).

(21) International Application Number:  
PCT/US2008/010414

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date:  
5 September 2008 (05.09.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/967,934 7 September 2007 (07.09.2007) US

(71) Applicant (for all designated States except US):  
SCINOPHARM TAIWAN LTD.; 1, Nan-ke 8th Road,  
Tainan Science-based Industrial Park, Tainan County, 741  
(TW).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: CHAN, Hardy [US/US]; 708 Vista Del Sol,  
San Mateo, CA 94404 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SHIH, Wen-li; No. 84, Shanding Lane, Shueili Township, Nantou County, 553 (TW). CHEN, Shu-ping; No. 56, Liaoning 2nd St., Kaohsiung City, Sanmin District, 807 (TW).

Published:  
— without international search report and to be republished upon receipt of that report



WO 2009/035535 A2

(54) Title: METHOD OF CRYSTALLIZING CARVEDILOL PHOSPHATE AND THE PRODUCT THEREOF

(57) Abstract: The present invention provides for a crystalline polymorph of Carvedilol phosphate salt and a process for making the same.

METHOD OF CRYSTALLIZING CARVEDILOL PHOSPHATE AND THE  
PRODUCT THEREOF

**BACKGROUND OF THE INVENTION**

**1. Field of the Invention**

5 [0001] The present application claims priority to  
Provisional Patent Application 60/967,934, filed  
September 7, 2007. The contents of this provisional  
patent application is hereby incorporated by reference.

**SUMMARY OF THE INVENTION**

10 [0002] The present invention provides a method of  
crystallizing Carvedilol-phosphate salt, and a novel  
crystalline polymorph of Carvedilol-phosphate salt.

**BRIEF DESCRIPTION OF THE DRAWINGS**

15 In the drawings:

[0003] Figure 1 shows the X-ray powder diffraction  
pattern of the crystalline polymorph of Carvedilol-  
phosphate salt of the present invention in intensity  
versus degrees in two theta.

20 [0004] Figure 2 is the diffuse reflectance spectrum of  
the crystalline polymorph of Carvedilol-phosphate salt  
of the present invention.

[0005] Figure 3 provides the peak positions within the  
diffuse reflectance spectrum of Figure 2, as well as an  
25 expansion of a certain region of that spectrum.

[0006] Figure 4 shows the X-ray powder diffraction  
pattern of the crystalline polymorph of Carvedilol-  
phosphate salt of the present invention in intensity  
versus d-spacing.

30 [0007] Figure 5 lists the peak positions and their  
intensities of the X-ray powder diffraction pattern of

the crystalline polymorph of Carvedilol-phosphate salt of the present invention.

**DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED**

5

**EMBODIMENTS**

[0008] The present invention provides a method of crystallizing Carvedilol-phosphate salt by the following procedure:

**Carvedilol phosphate salt formation**

10

[0009] To a solution of Carvedilol (5 g; 0.0123 mol.) in acetone (90 mL) is added 85% H<sub>3</sub>PO<sub>4</sub> (0.85 g; 0.0074 mol.) slowly. The resulting mixture is agitated at 20 - 30°C. The mixture is filtered and then washed with 20 mL  
15 acetone. The solids are dried under vacuum at <50°C to give 4.76 g Carvedilol-phosphate salt (hemihydrate).

[0010] Representative infrared spectrum and X-ray powder diffraction pattern for the Carvedilol-phosphate salt is  
20 provided herein.

## CLAIMS

We claim:

- 1 1. A crystalline polymorph of Carvedilol-phosphate salt  
2 exhibiting an X-ray powder diffraction pattern comprising  
3 a peak in degrees  $2\theta \pm 0.2^\circ$   $2\theta$  at 25.1.
  
- 1 2. A crystalline polymorph of Carvedilol-phosphate salt  
2 according to claim 1 further comprising peaks in degrees  
3  $2\theta \pm 0.2^\circ$   $2\theta$  at 24.1 and 23.6.
  
- 1 3. The crystalline polymorph of Carvedilol-phosphate salt  
2 according to claim 1 further comprising peaks in degrees  
3  $2\theta \pm 0.2^\circ$   $2\theta$  at 12.0 and 20.9.
  
- 1 4. The crystalline polymorph of Carvedilol-phosphate salt  
2 according to claim 1 exhibiting an X-ray powder  
3 diffraction pattern substantially as shown in Figure 1.
  
- 1 5. The crystalline polymorph of Carvedilol-phosphate salt  
2 according to claim 1 exhibiting an IR diffuse reflectance  
3 spectrum substantially as shown in Figure 2.
  
- 1 6. A method of preparing a crystalline polymorph of  
2 Carvedilol-phosphate salt comprising the steps of: (a)  
3 dissolving Carvedilol in acetone to form a solution; and  
4 (b) adding a solution comprising  $H_3PO_4$  to produce the  
5 crystalline polymorph of Carvedilol-phosphate salt.

XRD pattern of Carvedilol Phosphate:





FIGURE 1

IR pattern of Carvedilol Phosphate:





**FIGURE 2**

Thu Jun 14 18:10:24 2007

FIGURE 3

Title: SPT3172.B#2925-064-23



User name: MAGNA560

Collection time: Thu Jun 14 16:36:17 2007

Number of sample scans: 32

Number of background scans: 32

Resolution: 4.000

Sample gain: 8.0

Mirror velocity: 0.6329

Aperture: 100.00

Expanded fingerprint region:

File: 2925-064-23, ID: SPT3172API  
Date: 04/03/07 15:42 Step : 0.020° Cnt Time: 0.600 Sec.  
Range: 2.00 - 40.00 (Deg) Cent. Scan Rate : 2.00 Deg/min.




FIGURE 4



File: Untitled4

ID: SPR317ZAPI B#2925-064-23

Scan Type: Normal
Start Angle: 2 deg.
Stop Angle: 40 deg.
Num Points: 1901
Step Size: 0.02 deg.
Datafile Res: 1600
Scan Rate: 2.000000
Scan Mode: Continuous
Wavelength: 1.540562

Peaks:

Table with 12 columns: (Deg.), Position (NSP.), ESD (Deg.), Corr.Fact, Intensity (cps), Rel. Int. FWHM (L), ESD (Deg.), Area, Source, Curve, Strain, CSize, CSize Source. Contains 35 rows of peak data.

FIGURE 5